Primary Sjögren's syndrome followed by chronic myelogenous leukemia: a case report with a ten year history.
We describe a female patient with primary Sjögren's syndrome who subsequently developed chronic myelogenous leukemia. The patient received a bone marrow transplant (BMT) from a genotypically HLA-identical brother after pre-transplant preparation with busulfan and cyclophosphamide. Eighteen weeks later, cutaneous and mucosal chronic graft-versus-host disease developed, followed by death 11 months after transplantation. Anti-Ro/SS-A antibodies disappeared within 6 months post-BMT, but antinuclear antibodies remained positive through the post-transplant course.
Minowa
R
R
Department of Dermatology, Nara Medical University, Japan.
Miyagawa
S
S
Fukumoto
T
T
Majima
T
T
Shimoyama
T
T
Fujimura
Y
Y
Shirai
T
T
D000328:Adult; D000974:Antibodies, Antinuclear / Q000032:analysis; D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000628:therapy; D012859:Sjogren's Syndrome / Q000150:complications* / Q000276:immunology / Q000628:therapy; D019172:Transplantation Conditioning
D000974:Antibodies, Antinuclear; D007166:Immunosuppressive Agents; C035356:SS-A antibodies; D003520:Cyclophosphamide; D002066:Busulfan